Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products claiming to contain the active ingredient, semaglutide, for its popular weight-loss drug Wegovy.
The Danish drugmaker found these impurities to be as high as 33% in some instances, raising concerns about the safety and efficacy of the compounded drugs.
In the lawsuits filed in Florida on Wednesday, Novo Nordisk highlighted findings of impure substances in products from Wells Pharmacy and Brooksville Pharmaceuticals, both ...